All News
Demyelinating Disease is a Rare Complication of TNF Inhibition.
A recent review has shown that tumor necrosis factor-α inhibitors (TNFi) rarely cause MS-like disorders.
Read ArticleAnabolic Abaloparatide Looks Promising in Osteoporosis Fracture Prevention
The osteoporsis therapeutics arena is starting to fill with new drugs and novel mechanisms of action.
Read ArticleRheumNow Week in Review – 16 September 2016
A review of this week's news including the cost of opioid abuse, a RTX biosimilar, a new drug for scleroderma, a new shingles vaccine and a CPAP disappointment.
Read ArticleCDC Reports 31 Million Older Americans Don't Get Adequate Exercise
The Sept.16th issue of MMWR reports that many Americans over age 50 are not getting sufficient exercise, thereby increasing their risk for falls, fractures and comorbidities, if not premature death. (Citation source http://buff.ly/2cPAcq9)
Read ArticleNew Shingles Vaccine Effective for up to Four Years
In the current issue of the NEJM, a Herpes zoster subunit vaccine was reported to be highly effective in adults - specifically in 2 studies (ZOE50 and ZOE70) targeting adults over age 50 and over age 70 years. (Citation source: http://buff.ly/2cMng17)
Read ArticleDSB Reports and Updates - September 2016
Updates and journal articles on opioids, drug induced sarcoidosis, cancer and cancer recurrence risks with TNF inhibitors and biologics, and FDA labeling changes.
Read ArticleAdalimumab Lowers Risk of Uveitis Flares in Visual I Study
Rheumatologists may encounter patients with intermediate, posterior and pan-uveitis as part of certain rheumatic diseases such as Behcet’s, but more frequently may be called on to co-manage these patients with steroid sparing agents.
Read ArticleCPAP Use Fails to Prevent CV Events in Sleep Apnea Patients
There are numerous health hazards associated with obstructive sleep apnea (OSA), including an increased risk of cardiovascular events.
Read ArticleThe RheumNow Week in Review – 9 September 2016
Dr. Jack Cush reviews highlights from the past week on RheumNow.com, including IBD/TNFi and cancer risk, fracture nonunion, PMR worse in women, not treating asymptomatic hyperuricemia, and shingles followed by stroke.
Read ArticleIs Biologic Safety Different in the Elderly?
The factors that influence the safety of biologic therapy are numerous. Amongst them, increasing age is a potential risk factor, moreso if you also consider the polypharmacy, comorbidities and longer disease duration inherent in an elderly group of rheumatoid arthritis (RA) patients.
Read ArticleRheumNow Week in Review – 2 September 2016
Dr. Jack Cush reviews highlights from this week in RheumNow:
Read ArticleFlares Portend Damage in Rheumatoid Arthritis - Time for a New Strategy?
Disease flares are common in rheumatoid arthritis (RA), often causing patients to seek additional care, if not medication.
The frequency of flares varies amongst studies in different populations. But the consequence of flares has only recently been studied.
Read ArticleCost of Osteoporosis Care in the USA
The 2010 NHANES study suggests that the overall prevalence of osteoporosis (OP) in the USA is ~10% or 10.2 million older adults (> 50 yrs) had osteoporosis.
Read ArticleAnother Biosimilar Approval - Etanercep-szzs by Novartis
Yesterday the U.S. Food and Drug Administration approved a new biosimilar, Erelzi, (etanercept-szzs), for the same multipile indications as the originator Enbrel, including rheumatoid arthritis, plaque psoriasis, Erelzi, will be generically labelled as etanercept-szzs.
Read ArticleFDA Approves Updated Denosumab Warnings
In 2015, the Food and Drug Administration (FDA) updated the warnings of all marked bisphosphonates to include the risk of osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF).
Read ArticleZurampic Helps Allopurinol Non-Responders
Lesinurad (Zurampic) was approved earlier this year as adjunctive therapy to other urate-lowering therapies. It is a selective uric acid reabsorption inhibitor (URAT-1 inhibitor) designed to treat gout, and be used in combination with other xanthine oxidase inhibitors.
Read ArticleRheumNow Week in Review – 26 August 2016
Dr. Jack Cush reviews news and journal reports from the past week on RheumNow.com.
Read ArticleDrug Use Compounds Risk - Before and After Fragility Fractures
Is the occurrence of a fragility fracture a missed opportunity to reduce exposure to prescription drugs associated with fracture risk?
RheumNow Week in Review – 19 August 2016
Dr. Cush reviews the RheumNow.com highlights in rheumatology for the week ending 19 August 2016.
Read ArticleARCTIC Study Shows No Benefit to Ultrasound Remission in RA
The goal in rheumatoid arthritis (RA) treatment is remission. But what level or method of remission is best?
Read Article